U

Sedana Medical AB (publ) launches AnaConDa-S

  • 23 Mar 2017 15:08
Sedana Medical AB (publ) (“Sedana Medical” or “the Company”) is launching AnaConDa-S, a new innovation and an enhancement of its predecessor AnaConDa, in which the ‘dead volume’ has been halved from 100 ml to 50 ml. Halving the dead volume increases the potential market by around 25%.

AnaConDa-S is an enhancement of AnaConDa and is designed in a way that enables many more patients, including those with lower lung capacity, to be sedated, which was not possible with the older model. AnaConDa-S expands the target group by around 25 per cent, and the response from the health service has been very positive. Sedana Medical anticipates that AnaCon-Da will gradually replace the old AnaConDa model. 

The development work has been successfully carried out by Sedana Medical’s Development Department in Ireland, headed by Ron Farrell, COO/R&D. AnaConDa-S gained approval and a CE mark in Europe on 16 January 2017 and Germany will be first country in which it is launched in March 2017.  

“The development of a new generation of AnaConDa goes hand-in-hand with our ongoing efforts with a clinical study, which is intended to lead to marketing authorisation for our pharmaceutical IsoConDa® (isoflurane) for inhalation sedation in intensive care, and the expansion of our sales organisation. Since the start of the year, we have taken a major step towards realising our vision of making inhalation sedation with IsoConDa and AnaConDa a global standard method for the sedation of mechanically ventilated patients in intensive care,”  says Christer Ahlberg, CEO of Sedana Medical AB (publ). 

For further information, contact: 

Christer Ahlberg, CEO Sedana Medical AB (publ)
Mobile: +46 (0)70 – 675 33 30, Email: christer.ahlberg@sedanamedical.com 

_________________________

Sedana Medical AB (publ) is a Swedish company that develops, manufactures and sells the medical device AnaConDa. AnaConDa is a medical device for inhalation sedation of mechanically ventilated patients in intensive care units. At the end of 2016, the company initiated a major clinical study to receive market approval in Europe for IsoConDa (isoflurane) for inhalation sedation in intensive care units. The study is expected to end in late 2018. Registration is expected at the end of 2019. Sedana Medical has sales offices in Germany, Spain and France, as well as external distributors in Europe, the Middle East, Canada, Australia and South Korea. The headquarters is based in Danderyd, Sweden and the company has R&D operations in Ireland. 

AnaConDa-50ml Labeled 013-1
View All Press Releases